

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (canceled)

Claim 4 (currently amended): A method for the treatment of rheumatoid arthritis in a patient in need of such treatment comprising administering to the patient an effective amount of a CD25 binding molecule, wherein the CD25 binding molecule is basiliximab [[;]] wherein the CD25 binding molecule comprises:

(a) ~~first domain comprising the hypervariable regions CDR1, CDR2 and CDR3; the CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1), the CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2) and the CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Phe-Asp-Phe (SEQ ID NO:3) and~~

(b) ~~a second domain comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', the CDR1' having the amino acid sequence Ser-Ala-Ser-Ser-Ile-Ser-Tyr-Met-Gln (SEQ ID NO:4), the CDR2' having the amino acid sequence Asp-Thr-Ser-Lys-Leu-Ala-Ser (SEQ ID NO:5) and the CDR3' having the amino acid sequence His-Gln-Arg-Ser-Ser-Tyr-Thr (SEQ ID NO:6) .~~

Claim 5 (previously presented): The method of claim 4, further comprising administering to the patient an effective amount of a further drug substance being effective in the treatment of rheumatoid arthritis.

Claims 6-7 (canceled)

Claim 8 (currently amended) A method according to claim [[4]] 5 wherein the CD25 binding molecule is basiliximab further drug substance is at least one of cyclosporin A, cyclosporin G, FK-506, rapamycin, corticosteroids, cyclophosphamide, azathioprene, methotrexate, gold salts, sulfasalazine, antimalarials, brequinar, leflunomide, mizoribine,

mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualine, monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD28, B7, CD40, CD45 or CD58 receptors, or CTLA4Ig.

Claims 9-15 (canceled)